Biopharma Vital Signs
In 2026, biopharma has no shortage of scientific ambition – but the industry is also facing mounting pressure around funding, manufacturing, regulation, commercialization, and patient access
For Biopharma Vital Signs, The Medicine Maker asked industry experts for their views on the state of biotech and biopharma today. In six parts, contributors discuss the conversations shaping BIO 2026, the trends influencing development and manufacturing, the pressure points slowing progress, and the capabilities companies will need to move faster, more flexibly, and more resiliently.
The result is a snapshot of an industry in motion – one shaped by complex modalities, AI, supply chain uncertainty, shifting partnership models, and the ongoing challenge of turning innovation into therapies that can reliably reach patients.
Explore the full series below.
Biopharma Vital Signs – Part 1: Reading the Room at BIO
As BIO 2026 approaches, industry experts weigh in on the conversations likely to dominate the floor – from AI and funding pressures to manufacturing readiness, regulatory uncertainty, and the challenge of turning innovation into real-world impact.
Read the article
Biopharma Vital Signs – Part 2: Emerging Trends
Industry experts discuss the trends reshaping biotech and biopharma development – from complex modalities and manufacturing pressures to AI, funding constraints, and the growing need to plan for commercialization earlier.
Read the article
Biopharma Vital Signs – Part 3: Pressure Points
From clinical translation and regulatory expectations to manufacturing readiness, capital constraints, and commercial viability, experts identify the pressure points shaping the path from discovery to market
Read the article
Biopharma Vital Signs – Part 4: The New Partnership Playbook
Experts discuss how biopharma partnerships are evolving, as companies look beyond transactional supplier relationships toward more integrated, strategic, and collaborative models.
Read the article
Biopharma Vital Signs – Part 5: Capabilities for a Changing Landscape
Experts discuss the capabilities companies need to make drug development faster, more flexible, and more resilient – from integrated development and manufacturing flexibility to digital tools, supply chain strategy, and sharper decision-making.
Read the article